Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: Identification of new scaffolds for potent EGFR tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 5863-5867

  Kitano, Yasunori ^a   Suzuki, Tsuyoshi ^a   Kawahara, Eiji ^a   Yamazaki, Takahisa ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

4 Alkenylquinazoline; 4 Alkynylquinazoline; EGFR; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHIRALITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; ISOMER;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34548844203     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.020     Document Type: Article

References (33)

1. El-Zayat A.A.E., Pingree T.F., Mock P.M., Clark G.M., Otto R.A., and Von Hoff D.D. Cancer J. 4 (1991) 375
2. Morishige K., Kurachi H., Amemiya K., Fujita Y., Yamamoto T., Miyake A., and Tanizawa O. Cancer Res. 51 (1991) 5322
3. Jardines L., Weiss M., Fowble B., and Greene M. Pathobiology 61 (1993) 268
4. Hickey K., Grehan D., Reid I.M., O'Brian S., Walsh T.N., and Hennessy T.P. Cancer 74 (1994) 1693
5. Delarue J.C., Terrier P., Terrier-Lacombe M.J., Mouriesse H., Gotteland M., and May-Levin F. Bull. Cancer 81 (1994) 1067
6. Dobrusin E.M., and Fry D.W. Annu. Rep. Med. Chem. 27 (1992) 169
7. Vansteenkiste J.F. Expert Rev. Anticancer Ther. 4 (2004) 139
8. Tiseo M., Loprevite M., and Ardizzoni A. Curr. Med. Chem.: Anti-Cancer Agents 4 (2004) 139
9. Bonomi P. Exper. Opin. Invest. Drugs 12 (2003) 139
10. Bridges A.J. Curr. Med. Chem. 6 (1999) 825
11. For non-4-anilinoquinazoline EGFR-TK inhibitors, see. Bridges A.J., Cody D.R., Zhou H., McMichael A., and Fry D.W. Bioorg. Med. Chem. 3 (1995) 1651
12. Gibson K.H., Grundy W., Godfrey A.A., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Barker A.J., and Brown D.S. Bioorg. Med. Chem. Lett. 7 (1997) 2723
13. Bouey-Bencteux E., Loison C., Pommery N., Houssin R., and Hénichart J.-P. Anti-Cancer Drug Des. 13 (1998) 893
14. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Conners R.W., and Bridges A.J. Science 265 (1994) 1093
15. Sonogashira K., Tohda Y., and Hagihara N. Tetrahedron lett. 50 (1975) 4467
16. Barker, A. J. EP 566,226, 1995.
17. Bridges A.J., Zhou H., Cody D.R., Rewcastle G.W., McMichael A., Showalter H.D.H., Fry D.W., Kraker A.J., and Denny W.A. J. Med. Chem. 39 (1996) 267
18. Hennion G.F., and Hanzel R.S. J. Am. Chem. Soc. 82 (1960) 4908
19. Corey E.J., and Fuchs P.L. Tetrahedron Lett. (1972) 3769
20. For a review, see. Eymery F., Iorga B., and Savignac P. Synthesis (2000) 185
21. Frey H., and Kaupp G. Synthesis (1990) 931
22. Imada Y., Yuasa M., Nakamura I., and Murahashi S.-I. J. Org. Chem. 59 (1994) 2282
23. Negishi E., Takahashi T., Van Horn D.E., and Okukado N. J. Am. Chem. Soc. 109 (1987) 2393
24. 50 values are representative of at least two independent experiments
25. Compound 4d:. Purohit V.G., and Subramanian R. Chem. Ind. (1978) 731
26. Compound 4n:. Ghosez L., Cécile F., Frédéric D., Cuisinier C., and Touillaux R. Can. J. Chem. 79 (2001) 1827
27. Compound 4n: Dority, J. A. Jr.; Earley, W. G.; Kumar, V.; Mallamo, J. P.; Miller, M. S.; Subramanyanm, C. U. S. Patent 5,569,655, 1996.
28. Compound 4p:. Kira M.A., Aboul-Enein M.N., and KorKor M.I. J. Heterocycl. Chem. 7 (1970) 25
29. Hamatake, R. K.; Chen, H.; Raney, A.; Allan, M. J.; Lang, S. WO 2006033995.
30. Stamos J., Sliwkowski M.X., and Eigenbrot C. J. Biol. Chem. 277 (2002) 46265
31. The conformational ensemble and the local energy minimization of the poses (∼1 kcal/mol) for 2b and 6b were performed using the Insight II software (Accelrys Software Inc.).
32. Separation and determination of optical purity were performed using CHIRALPAK AD (Daicel Chemical Industries, Ltd).
33. 3).